Does workers' comp cover ketamine or nerve blocks for CRPS?
California workers' compensation pays for ketamine infusions or sympathetic nerve blocks for CRPS only when the treatment is found medically necessary under the Medical Treatment Utilization Schedule. Each request goes through utilization review. A denial can be appealed through independent medical review within 30 days. In 2025, independent medical review overturned 11 percent of the nerve block denials it decided.

What decides whether workers' comp pays for a CRPS treatment in California?
Medical necessity decides it. Labor Code section 4600 requires the employer to provide treatment "that is reasonably required to cure or relieve the injured worker from the effects of the worker's injury," and defines that phrase as treatment "based upon the guidelines adopted by the administrative director." Those guidelines are the Medical Treatment Utilization Schedule (MTUS).
Section 4600 does not list ketamine infusions or sympathetic nerve blocks as covered or excluded. Each request from the treating physician is measured against the MTUS in utilization review. Why CRPS treatment is denied and how to appeal describes that process and its deadlines.
Which guideline applies to ketamine and nerve blocks for CRPS?
The MTUS chronic pain guideline applies. California Code of Regulations, title 8, section 9792.24.2 adopts the Chronic Pain Guideline of the American College of Occupational and Environmental Medicine (ACOEM) dated December 22, 2025, and states that the guideline addresses "complex regional pain syndrome, fibromyalgia, neuropathic pain."
The guideline text is licensed. The Division of Workers' Compensation states that providers who treat, evaluate or perform utilization review in California workers' compensation can register for access at no cost. This page does not restate the guideline's recommendations on ketamine or nerve blocks. A utilization review denial must cite the guideline or study the reviewer relied on, under section 9792.21.1 of the regulations, so the denial letter shows which recommendation was applied.
Can a treatment the guideline does not support still be approved?
Yes, in two situations the regulations describe. The first is a gap in the guideline. California Code of Regulations, title 8, section 9792.21(d) states, "Treatment shall not be denied on the sole basis that the condition or injury is not addressed by the MTUS." The reviewer must then look to other guidelines and peer-reviewed studies in a set order.
The second is rebuttal by the treating physician. The MTUS presumption is overcome "by a preponderance of scientific medical evidence establishing that a variance from the schedule is reasonably required." Section 9792.21.1 requires the physician to state in the request that the presumption is being challenged and to attach the study or guideline section relied on.
What have studies of ketamine infusions for CRPS found?
Studies of ketamine infusions for CRPS report pain relief that lasts weeks, not months. In a 2009 randomized trial by Sigtermans and colleagues, 60 people with CRPS type I received a 4.2-day intravenous ketamine infusion or placebo. The lowest pain score, in week one, was 2.68 with ketamine and 5.45 with placebo. By week 12 the difference was no longer significant.
A 2026 meta-analysis of 21 studies and 605 patients found a mean pain reduction of 3.6 points within 14 days from a baseline of 7.4, with "a gradual return toward baseline" by 90 days (van den Brink, 2026). A 2018 meta-analysis concluded that ketamine gave "clinically effective pain relief in short term for less than 3 months" (Zhao, 2018).
Is ketamine approved by the FDA for CRPS?
No. Ketamine is approved as an anesthetic. A 2022 article in ASRA Pain Medicine News, published by the American Society of Regional Anesthesia and Pain Medicine, states, "Currently, there is no FDA-approved indication for using ketamine infusion as a treatment modality." Use for CRPS is off label.
Ketamine is not alone in that respect. The National Institute of Neurological Disorders and Stroke states that the medicines used for CRPS are used "off label," which means they are approved for other conditions. Approval status is not one of the six medical necessity standards listed in Labor Code section 4610.5, which begin with the adopted guidelines and peer-reviewed evidence of effectiveness.
What have studies of sympathetic nerve blocks for CRPS found?
Controlled studies have not shown that sympathetic nerve blocks reduce CRPS pain more than placebo. A 2016 Cochrane review covered 12 studies with 461 participants, and its two small placebo-controlled trials "did not demonstrate significant short-term benefit." A 2023 Cochrane overview found "moderate-certainty evidence that lidocaine local anaesthetic sympathetic blockade probably does not reduce pain intensity compared with placebo."
Sympathetic blocks remain in use. The 2022 practical guidelines in Pain Medicine describe the role of the block as "largely empiric." In a 1998 study of seven patients, saline produced nearly the same peak pain relief as local anesthetic, and the two differed mainly in how long relief lasted (Price, 1998).
How often are nerve block denials overturned in independent medical review?
About one time in nine. The Division of Workers' Compensation's 2026 report counted 1,081 disputed nerve block requests decided in 2025. Reviewers upheld 958 denials, or 89 percent, and overturned 123, or 11 percent. The row covers nerve blocks for every diagnosis, and it is not limited to sympathetic blocks or to CRPS.
| Service | Denials reviewed | Denials upheld | Denials overturned |
|---|---|---|---|
| Nerve block | 1,081 | 958 (89 percent) | 123 (11 percent) |
| Trigger point injection | 1,587 | 1,447 (91 percent) | 140 (9 percent) |
| All peripheral injections | 13,989 | 12,903 (92 percent) | 1,086 (8 percent) |
| All spine injections | 10,978 | 10,384 (95 percent) | 594 (5 percent) |
Does the state report how ketamine denials fare on appeal?
No. The Division of Workers' Compensation's 2026 report on independent medical review has no row for ketamine infusions, and it does not report outcomes by diagnosis. The report's tables list drugs by class and procedures by type. Individual decisions are posted on the division's website with identifying details removed, and the division's search tool cannot search them by drug or diagnosis. The division's annual report therefore gives no figure for how often a ketamine denial for CRPS is overturned.
How do I appeal a ketamine or nerve block denial in California?
The appeal is a request for independent medical review on the DWC IMR-1 form that comes with the denial. Labor Code section 4610.5(h) sets the deadline at 30 days after the utilization review decision is served on the worker. The worker may send the treating physician's recommendation and supporting information, and the requesting physician may advocate for the worker.
An expedited review is available when treatment has not been provided and the provider certifies "an imminent and serious threat to the health of the employee," which Labor Code section 4610.6(d) says includes "serious pain." An expedited determination is due within three days after the reviewer receives the information.
Can a series of nerve blocks or infusions be requested again after a denial?
A repeat request for the same treatment within 12 months needs a documented change. Labor Code section 4610(k) keeps a denial effective "for 12 months from the date of the decision" as to the same treatment from the same physician or practice group, unless the new recommendation "is supported by a documented change in the facts material to the basis of the utilization review decision."
Garibay v. Scientific Drilling International (2024), a Workers' Compensation Appeals Board panel decision, gives one example. The medical evaluator reported that the worker "had significant pain relief after that block for several weeks" and that "further blocks and treatment for her CRPS were not authorized."
Who pays if I get ketamine without workers' comp approval?
The worker bears that cost unless the denial is overturned. Labor Code section 4610.5(e) states that neither the employee nor the employer is liable for treatment furnished without authorization after a utilization review denial, "unless the utilization review decision is overturned by independent medical review." The 2022 ASRA Pain Medicine News article put the cost to a patient at "anywhere between $415-$1,350 per infusion session," and CRPS protocols in the trials ran for several days.
Common questions
Sources
Every source below was opened and read for this page. The date is when it was last checked.
- Labor Code section 4600Statute · California Legislative Information · checked
- Labor Code section 4604.5Statute · California Legislative Information · checked
- Labor Code section 4610Statute · California Legislative Information · checked
- Labor Code section 4610.5Statute · California Legislative Information · checked
- Labor Code section 4610.6Statute · California Legislative Information · checked
- California Code of Regulations, title 8, section 9792.21 (Medical Treatment Utilization Schedule)Regulation · California Department of Industrial Relations · checked
- California Code of Regulations, title 8, section 9792.21.1 (Medical Evidence Search Sequence)Regulation · California Department of Industrial Relations · checked
- California Code of Regulations, title 8, section 9792.24.2 (Chronic Pain Guidelines)Regulation · California Department of Industrial Relations, 2026 · checked
- Medical Treatment Utilization ScheduleGovernment agency · California Department of Industrial Relations, Division of Workers' Compensation · checked
- 2026 Independent Medical Review (IMR) Report: Analysis of 2025 DataGovernment agency · California Department of Industrial Relations, Division of Workers' Compensation, 2026 · checked
- Garibay v. Scientific Drilling International, Inc. (March 15, 2024) ADJ15533334, opinion and order denying petition for reconsiderationCourt opinion · Workers' Compensation Appeals Board (panel decision), 2024 · checked
- Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1Study · Pain (Sigtermans et al.), 2009 · checked
- The Effect of Ketamine Infusion in the Treatment of Complex Regional Pain Syndrome: a Systemic Review and Meta-analysisStudy · Current Pain and Headache Reports (Zhao et al.), 2018 · checked
- Intravenous ketamine for complex regional pain syndrome: Pain outcomes and predictors of response. A systematic review and meta-analysisStudy · The Journal of Pain (van den Brink et al.), 2026 · checked
- Ketamine Infusion Therapy and Its Role in Chronic PainOrganization · ASRA Pain Medicine News (Goordeen et al.), 2022 · checked
- Local anaesthetic sympathetic blockade for complex regional pain syndromeStudy · Cochrane Database of Systematic Reviews (O'Connell et al.), 2016 · checked
- Interventions for treating pain and disability in adults with complex regional pain syndrome: an overview of systematic reviewsStudy · Cochrane Database of Systematic Reviews (Ferraro et al.), 2023 · checked
- Analysis of peak magnitude and duration of analgesia produced by local anesthetics injected into sympathetic ganglia of complex regional pain syndrome patientsStudy · The Clinical Journal of Pain (Price et al.), 1998 · checked
- Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th EditionClinical guideline · Pain Medicine (Harden et al.), 2022 · checked
- Complex Regional Pain SyndromeGovernment agency · National Institute of Neurological Disorders and Stroke · checked

Workers' compensation and CRPS
Ketamine infusions
CRPS symptom diary